Sells COVID and RSV vaccines to governments and commercial buyers, while developing mRNA vaccines and treatments for infectious diseases, cancer and rare diseases.
10-K for FY2025, filed Feb 20, 2026We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory…View ↗
Beyond our commercial products, we continue to demonstrate the potential of our platform technology and are advancing a pipeline of…View ↗
In infectious disease, we have regulatory filings under review for our seasonal flu+COVID combination vaccine candidate (mRNA-1083) in…View ↗
In rare disease, our propionic acidemia therapeutic (mRNA-3927) has reached target enrollment in a registrational study. In January 2026…View ↗
Customers pay for COVID and RSV vaccines, with product sales counted when the vaccines are delivered. Other revenue comes from research grants, collaboration work, licenses and royalties, and manufacturing-capacity agreements; payment timing varies by arrangement.
10-K for FY2025, filed Feb 20, 2026We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S.…View ↗
We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally…View ↗
Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing…View ↗
We have contracts with government-sponsored and private organizations for research and development related activities that provide for…View ↗
We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses…View ↗
License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty…View ↗
$1.9B
10-K for FY2025, filed Feb 20, 2026
$1.9B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 20, 2026 |
94%
FY2022: 96%
|
Net product sales, FY2025
$1.8B Sources
|
Sold outright |
|
Other revenue
|
6.5% |
Other revenue, FY2025
$126M Sources
|
Moderna sells vaccines to commercial buyers, foreign governments and international organizations. In the U.S., wholesalers and distributors are the main route to market, with some direct sales to retailers and healthcare providers; it also works with government entities, grant organizations and strategic collaborators.
10-K for FY2025, filed Feb 20, 2026We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S.…View ↗
We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our…View ↗
Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales…View ↗
No. It lost $2.8B in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
$162MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
8-K, filed Nov 6, 2026
Increases 2026 expected revenue growth to 15%–25%, exceeding the previous expectation of up to 10% growthView ↗
8-K, filed Mar 5, 2026
On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and…View ↗
Shrinking. Revenue fell 89% in 4 years, from $18.5B in FY2021 to $1.9B in FY2025, about 43% a year.
Commercial products
The older report described Spikevax as its first approved product and focused on the potential launch of RSV, flu and combination vaccines. The latest report lists three commercial products, including COVID and RSV vaccines, and describes a broader pipeline spanning infectious disease, oncology and rare disease.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Feb 20, 2026We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory…View ↗
Beyond our commercial products, we continue to demonstrate the potential of our platform technology and are advancing a pipeline of…View ↗
In infectious disease, we have regulatory filings under review for our seasonal flu+COVID combination vaccine candidate (mRNA-1083) in…View ↗
In rare disease, our propionic acidemia therapeutic (mRNA-3927) has reached target enrollment in a registrational study. In January 2026…View ↗
Competes with Pfizer, BioNTech, Sanofi, Novavax, and GlaxoSmithKline
10-K for FY2025, filed Feb 20, 2026We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also…View ↗
Loading...